Mary Hobart, PhD

  • 5Articles
  • 35.4KReads
  • 2015–2025Active
  • 20Collaborators
  • 370Citations

About

Mary Hobart, PhD, is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc. in Princeton, New Jersey. Her work, published between 2015 and 2025 in Psychiatrist.com, focuses on topics including depression, posttraumatic stress disorder, psychiatry, and schizophrenia/schizoaffective disorders. She has co-authored articles with Aleksandar Skuban, Nanco Hefting, Peter Zhang, Raymond Sanchez, and Robert D. McQuade.

Publications

JCP
Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial
Original Research

Brexpiprazole in Combination with Sertraline and as Monotherapy in PTSD: A Full-Factorial Randomized Clinical Trial

February 19, 2025

In this 10-week study, brexpiprazole in combination with sertraline, but not as monotherapy, demonstrated the potential to be a new efficacious treatment for PTSD.
, , , et al
JCP
Effects of Brexpiprazole on Functioning in Schizophrenia
Original Research

Effects of Brexpiprazole on Functioning in Schizophrenia

March 1, 2022

Drawing on 4 RCTs and 2 open-label extension studies of brexpiprazole, this analysis looks at the effects of this medication on functioning both in the short term and over...
, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Brexpiprazole in MDD

May 22, 2018

Finding effective treatment for depressed patients who do not adequately respond to antidepressant medications is a frequent challenge for clinicians. Read this article to learn about the efficacy, safety,...
, , , et al
JCP
Original Research

Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study

September 23, 2015

, , , et al
JCP
Original Research

Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants

September 23, 2015

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe